New combo before transplant aims to beat High-Risk leukemia
NCT ID NCT03494569
First seen Nov 10, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new, stronger conditioning regimen—combining targeted radiation (TMLI) with two chemotherapy drugs—given before a donor stem cell transplant. The goal is to find the safest dose that can destroy cancer cells while allowing the donor cells to take hold. The study is currently on hold and involves 36 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.